{
  "study_id": "TCOG0701",
  "study_title": "A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial",
  "table_name": "Table 1",
  "table_title": "Patient characteristics",
  "description": "Baseline demographic and clinical characteristics of patients in the S-1 plus cisplatin group and the docetaxel plus cisplatin group.",
  "footnotes": [],
  "groups": [
    {
      "name": "S-1 plus cisplatin",
      "n": 301,
      "type": "intervention"
    },
    {
      "name": "Docetaxel plus cisplatin",
      "n": 295,
      "type": "intervention"
    }
  ],
  "characteristics": [
    {
      "original_label": "Age, years",
      "standardized_name": "Age",
      "unit": "years",
      "category": "Demographics",
      "group_data": [
        {
          "group_name": "S-1 plus cisplatin",
          "data_type": "header",
          "raw_string": "Age, years"
        },
        {
          "group_name": "Docetaxel plus cisplatin",
          "data_type": "header",
          "raw_string": "Age, years"
        }
      ]
    },
    {
      "original_label": "Average (SD)",
      "standardized_name": "Age",
      "unit": "years",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Age",
      "group_data": [
        {
          "group_name": "S-1 plus cisplatin",
          "data_type": "numeric_mean_sd",
          "mean": 61.4,
          "std_dev": 8.7,
          "raw_string": "61.4 (8.7)"
        },
        {
          "group_name": "Docetaxel plus cisplatin",
          "data_type": "numeric_mean_sd",
          "mean": 62.8,
          "std_dev": 7.8,
          "raw_string": "62.8 (7.8)"
        }
      ]
    },
    {
      "original_label": "Median (range)",
      "standardized_name": "Age",
      "unit": "years",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Age",
      "group_data": [
        {
          "group_name": "S-1 plus cisplatin",
          "data_type": "numeric_median_iqr",
          "median": 62.0,
          "iqr_min": 25.0,
          "iqr_max": 74.0,
          "raw_string": "62 (25-74)"
        },
        {
          "group_name": "Docetaxel plus cisplatin",
          "data_type": "numeric_median_iqr",
          "median": 64.0,
          "iqr_min": 35.0,
          "iqr_max": 74.0,
          "raw_string": "64 (35-74)"
        }
      ]
    },
    {
      "original_label": "Gender",
      "standardized_name": "Sex",
      "category": "Demographics",
      "group_data": [
        {
          "group_name": "S-1 plus cisplatin",
          "data_type": "header",
          "raw_string": "Gender"
        },
        {
          "group_name": "Docetaxel plus cisplatin",
          "data_type": "header",
          "raw_string": "Gender"
        }
      ]
    },
    {
      "original_label": "Male",
      "standardized_name": "Sex",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Sex",
      "group_data": [
        {
          "group_name": "S-1 plus cisplatin",
          "data_type": "categorical_count_percentage",
          "count": 211.0,
          "percentage": 70.1,
          "raw_string": "211 (70.1%)",
          "n_for_value": 301
        },
        {
          "group_name": "Docetaxel plus cisplatin",
          "data_type": "categorical_count_percentage",
          "count": 208.0,
          "percentage": 70.5,
          "raw_string": "208 (70.5%)",
          "n_for_value": 295
        }
      ]
    },
    {
      "original_label": "Female",
      "standardized_name": "Sex",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Sex",
      "group_data": [
        {
          "group_name": "S-1 plus cisplatin",
          "data_type": "categorical_count_percentage",
          "count": 90.0,
          "percentage": 29.9,
          "raw_string": "90 (29.9%)",
          "n_for_value": 301
        },
        {
          "group_name": "Docetaxel plus cisplatin",
          "data_type": "categorical_count_percentage",
          "count": 87.0,
          "percentage": 29.5,
          "raw_string": "87 (29.5%)",
          "n_for_value": 295
        }
      ]
    },
    {
      "original_label": "Histology",
      "standardized_name": "Histology",
      "category": "Disease Characteristics",
      "group_data": [
        {
          "group_name": "S-1 plus cisplatin",
          "data_type": "header",
          "raw_string": "Histology"
        },
        {
          "group_name": "Docetaxel plus cisplatin",
          "data_type": "header",
          "raw_string": "Histology"
        }
      ]
    },
    {
      "original_label": "Adenocarcinoma",
      "standardized_name": "Histology",
      "category": "Disease Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Histology",
      "group_data": [
        {
          "group_name": "S-1 plus cisplatin",
          "data_type": "categorical_count_percentage",
          "count": 228.0,
          "percentage": 75.8,
          "raw_string": "228 (75.8%)",
          "n_for_value": 301
        },
        {
          "group_name": "Docetaxel plus cisplatin",
          "data_type": "categorical_count_percentage",
          "count": 222.0,
          "percentage": 75.3,
          "raw_string": "222 (75.3%)",
          "n_for_value": 295
        }
      ]
    },
    {
      "original_label": "Squamous cell carcinoma",
      "standardized_name": "Histology",
      "category": "Disease Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Histology",
      "group_data": [
        {
          "group_name": "S-1 plus cisplatin",
          "data_type": "categorical_count_percentage",
          "count": 50.0,
          "percentage": 16.6,
          "raw_string": "50 (16.6%)",
          "n_for_value": 301
        },
        {
          "group_name": "Docetaxel plus cisplatin",
          "data_type": "categorical_count_percentage",
          "count": 48.0,
          "percentage": 16.3,
          "raw_string": "48 (16.3%)",
          "n_for_value": 295
        }
      ]
    },
    {
      "original_label": "Large-cell carcinoma",
      "standardized_name": "Histology",
      "category": "Disease Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Histology",
      "group_data": [
        {
          "group_name": "S-1 plus cisplatin",
          "data_type": "categorical_count_percentage",
          "count": 5.0,
          "percentage": 1.7,
          "raw_string": "5 (1.7%)",
          "n_for_value": 301
        },
        {
          "group_name": "Docetaxel plus cisplatin",
          "data_type": "categorical_count_percentage",
          "count": 5.0,
          "percentage": 1.7,
          "raw_string": "5 (1.7%)",
          "n_for_value": 295
        }
      ]
    },
    {
      "original_label": "Adenosquamous carcinoma",
      "standardized_name": "Histology",
      "category": "Disease Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Histology",
      "group_data": [
        {
          "group_name": "S-1 plus cisplatin",
          "data_type": "categorical_count_percentage",
          "count": 7.0,
          "percentage": 2.3,
          "raw_string": "7 (2.3%)",
          "n_for_value": 301
        },
        {
          "group_name": "Docetaxel plus cisplatin",
          "data_type": "categorical_count_percentage",
          "count": 1.0,
          "percentage": 0.3,
          "raw_string": "1 (0.3%)",
          "n_for_value": 295
        }
      ]
    },
    {
      "original_label": "Other",
      "standardized_name": "Histology",
      "category": "Disease Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Histology",
      "group_data": [
        {
          "group_name": "S-1 plus cisplatin",
          "data_type": "categorical_count_percentage",
          "count": 11.0,
          "percentage": 3.7,
          "raw_string": "11 (3.7%)",
          "n_for_value": 301
        },
        {
          "group_name": "Docetaxel plus cisplatin",
          "data_type": "categorical_count_percentage",
          "count": 19.0,
          "percentage": 6.4,
          "raw_string": "19 (6.4%)",
          "n_for_value": 295
        }
      ]
    },
    {
      "original_label": "Clinical stage",
      "standardized_name": "Clinical Stage",
      "category": "Disease Characteristics",
      "group_data": [
        {
          "group_name": "S-1 plus cisplatin",
          "data_type": "header",
          "raw_string": "Clinical stage"
        },
        {
          "group_name": "Docetaxel plus cisplatin",
          "data_type": "header",
          "raw_string": "Clinical stage"
        }
      ]
    },
    {
      "original_label": "Stage IIIB",
      "standardized_name": "Clinical Stage",
      "category": "Disease Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Clinical Stage",
      "group_data": [
        {
          "group_name": "S-1 plus cisplatin",
          "data_type": "categorical_count_percentage",
          "count": 79.0,
          "percentage": 26.3,
          "raw_string": "79 (26.3%)",
          "n_for_value": 301
        },
        {
          "group_name": "Docetaxel plus cisplatin",
          "data_type": "categorical_count_percentage",
          "count": 78.0,
          "percentage": 26.4,
          "raw_string": "78 (26.4%)",
          "n_for_value": 295
        }
      ]
    },
    {
      "original_label": "Stage IV",
      "standardized_name": "Clinical Stage",
      "category": "Disease Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Clinical Stage",
      "group_data": [
        {
          "group_name": "S-1 plus cisplatin",
          "data_type": "categorical_count_percentage",
          "count": 201.0,
          "percentage": 66.8,
          "raw_string": "201 (66.8%)",
          "n_for_value": 301
        },
        {
          "group_name": "Docetaxel plus cisplatin",
          "data_type": "categorical_count_percentage",
          "count": 192.0,
          "percentage": 65.1,
          "raw_string": "192 (65.1%)",
          "n_for_value": 295
        }
      ]
    },
    {
      "original_label": "Postoperative recurrence",
      "standardized_name": "Clinical Stage",
      "category": "Disease Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Clinical Stage",
      "group_data": [
        {
          "group_name": "S-1 plus cisplatin",
          "data_type": "categorical_count_percentage",
          "count": 21.0,
          "percentage": 7.0,
          "raw_string": "21 (7.0%)",
          "n_for_value": 301
        },
        {
          "group_name": "Docetaxel plus cisplatin",
          "data_type": "categorical_count_percentage",
          "count": 25.0,
          "percentage": 8.5,
          "raw_string": "25 (8.5%)",
          "n_for_value": 295
        }
      ]
    },
    {
      "original_label": "ECOG performance status",
      "standardized_name": "ECOG Performance Status",
      "category": "Disease Characteristics",
      "group_data": [
        {
          "group_name": "S-1 plus cisplatin",
          "data_type": "header",
          "raw_string": "ECOG performance status"
        },
        {
          "group_name": "Docetaxel plus cisplatin",
          "data_type": "header",
          "raw_string": "ECOG performance status"
        }
      ]
    },
    {
      "original_label": "0",
      "standardized_name": "ECOG Performance Status",
      "category": "Disease Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "ECOG Performance Status",
      "group_data": [
        {
          "group_name": "S-1 plus cisplatin",
          "data_type": "categorical_count_percentage",
          "count": 151.0,
          "percentage": 50.2,
          "raw_string": "151 (50.2%)",
          "n_for_value": 301
        },
        {
          "group_name": "Docetaxel plus cisplatin",
          "data_type": "categorical_count_percentage",
          "count": 152.0,
          "percentage": 51.5,
          "raw_string": "152 (51.5%)",
          "n_for_value": 295
        }
      ]
    },
    {
      "original_label": "1",
      "standardized_name": "ECOG Performance Status",
      "category": "Disease Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "ECOG Performance Status",
      "group_data": [
        {
          "group_name": "S-1 plus cisplatin",
          "data_type": "categorical_count_percentage",
          "count": 150.0,
          "percentage": 49.8,
          "raw_string": "150 (49.8%)",
          "n_for_value": 301
        },
        {
          "group_name": "Docetaxel plus cisplatin",
          "data_type": "categorical_count_percentage",
          "count": 143.0,
          "percentage": 48.5,
          "raw_string": "143 (48.5%)",
          "n_for_value": 295
        }
      ]
    },
    {
      "original_label": "Smoking status",
      "standardized_name": "Smoking Status",
      "category": "Demographics",
      "group_data": [
        {
          "group_name": "S-1 plus cisplatin",
          "data_type": "header",
          "raw_string": "Smoking status"
        },
        {
          "group_name": "Docetaxel plus cisplatin",
          "data_type": "header",
          "raw_string": "Smoking status"
        }
      ]
    },
    {
      "original_label": "Previous/current smoker",
      "standardized_name": "Smoking Status",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Smoking Status",
      "group_data": [
        {
          "group_name": "S-1 plus cisplatin",
          "data_type": "categorical_count_percentage",
          "count": 223.0,
          "percentage": 74.1,
          "raw_string": "223 (74.1%)",
          "n_for_value": 301
        },
        {
          "group_name": "Docetaxel plus cisplatin",
          "data_type": "categorical_count_percentage",
          "count": 222.0,
          "percentage": 75.3,
          "raw_string": "222 (75.3%)",
          "n_for_value": 295
        }
      ]
    },
    {
      "original_label": "Never smoker",
      "standardized_name": "Smoking Status",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Smoking Status",
      "group_data": [
        {
          "group_name": "S-1 plus cisplatin",
          "data_type": "categorical_count_percentage",
          "count": 78.0,
          "percentage": 25.9,
          "raw_string": "78 (25.9%)",
          "n_for_value": 301
        },
        {
          "group_name": "Docetaxel plus cisplatin",
          "data_type": "categorical_count_percentage",
          "count": 73.0,
          "percentage": 24.8,
          "raw_string": "73 (24.8%)",
          "n_for_value": 295
        }
      ]
    },
    {
      "original_label": "EGFR status",
      "standardized_name": "EGFR Status",
      "category": "Biomarkers",
      "group_data": [
        {
          "group_name": "S-1 plus cisplatin",
          "data_type": "header",
          "raw_string": "EGFR status"
        },
        {
          "group_name": "Docetaxel plus cisplatin",
          "data_type": "header",
          "raw_string": "EGFR status"
        }
      ]
    },
    {
      "original_label": "Wild type",
      "standardized_name": "EGFR Status",
      "category": "Biomarkers",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "EGFR Status",
      "group_data": [
        {
          "group_name": "S-1 plus cisplatin",
          "data_type": "categorical_count_percentage",
          "count": 113.0,
          "percentage": 37.5,
          "raw_string": "113 (37.5%)",
          "n_for_value": 301
        },
        {
          "group_name": "Docetaxel plus cisplatin",
          "data_type": "categorical_count_percentage",
          "count": 115.0,
          "percentage": 39.0,
          "raw_string": "115 (39.0%)",
          "n_for_value": 295
        }
      ]
    },
    {
      "original_label": "Mutant",
      "standardized_name": "EGFR Status",
      "category": "Biomarkers",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "EGFR Status",
      "group_data": [
        {
          "group_name": "S-1 plus cisplatin",
          "data_type": "categorical_count_percentage",
          "count": 43.0,
          "percentage": 14.3,
          "raw_string": "43 (14.3%)",
          "n_for_value": 301
        },
        {
          "group_name": "Docetaxel plus cisplatin",
          "data_type": "categorical_count_percentage",
          "count": 46.0,
          "percentage": 15.6,
          "raw_string": "46 (15.6%)",
          "n_for_value": 295
        }
      ]
    },
    {
      "original_label": "Unknown or missing",
      "standardized_name": "EGFR Status",
      "category": "Biomarkers",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "EGFR Status",
      "group_data": [
        {
          "group_name": "S-1 plus cisplatin",
          "data_type": "categorical_count_percentage",
          "count": 145.0,
          "percentage": 48.2,
          "raw_string": "145 (48.2%)",
          "n_for_value": 301
        },
        {
          "group_name": "Docetaxel plus cisplatin",
          "data_type": "categorical_count_percentage",
          "count": 134.0,
          "percentage": 45.4,
          "raw_string": "134 (45.4%)",
          "n_for_value": 295
        }
      ]
    }
  ]
}